Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Dioseve logo — creating human eggs from iPS cells

Dioseve

creating human eggs from iPS cells

Founded 2021 Japan Japan 5 employees Total: $407.00M Biotechnology, Health Care

General Information

Company Name Dioseve
Founded Year 2021
Location Japan Japan
Employees 5
Industries Biotechnology, Health Care
Business Model B2B, B2C, B2D
Revenue Model Service Fee, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Dioseve. To contact Dioseve, visit dioseve.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Dioseve compare?

A PDF of Dioseve and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Dioseve soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Dioseve

Dioseve is a burgeoning player in the Biotechnology and Health Care industries, poised to transform infertility treatments. Founded in 2021, the company is headquartered in Japan and is devoted to the pioneering mission of "creating human eggs from iPS cells." Through its cutting-edge technology that develops fertilizable eggs from iPS and ES cells, Dioseve aims to offer revolutionary solutions for couples facing infertility.

Recently, the company secured a substantial ¥1.00 billion in Series A funding on 27 June 2024. This investment round saw participation from notable venture capital firms, including ANRI, Archetype Ventures, DG Daiwa Ventures, Future Venture Capital, Spiral Capital, and QR Investment. This financial backing underscores confidence in Dioseve's innovative approach and its potential impact on the global infertility treatment market. As Dioseve continues to advance its research and development efforts, it stands at the forefront of a significant medical breakthrough.

Business keywords: iPS cells, ES cells, fertility technology, oocyte creation, infertility treatment, reproductive innovation, stem cell research, fertility solutions, reproductive health

Services & Products

developing solutions for infertility using stem cell technology
inducing egg and sperm cells from iPS cells
innovative reproductive health solutions

Target Customers

individuals facing infertility couples desiring children healthcare providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC $7.00M 6
ANRI Archetype Ventures DG Daiwa Ventures
ANRI, Archetype Ventures +4
01 Jun 2024
Seed ¥400.00M 2
ANRI Coral Capital
ANRI, Coral Capital
01 Aug 2022

Dioseve Alternatives & Competitors

View All Alternatives
Dioseve vs
Pinnacle Washington
Pinnacle Washington United States

Part of the Pinnacle Fertility Network.

150 employees
Biotechnology, Health Care
Dioseve vs
Ivy Natal
Ivy Natal United States

Unlocking human fertility. Learn more at https://www.ivynatal.com.

Venture round
4 employees
Biotechnology, Health Care
Dioseve vs
IRMS Institute for Reproductive Medicine
IRMS Institute for Reproductive Medicine United States

At IRMS, we’re changing the way the world looks at fertility.

57 employees
Biotechnology, Health Care
View all alternatives

FAQ About Dioseve

creating human eggs from iPS cells
Dioseve was founded in 2021.
Dioseve is headquartered in Japan.
Dioseve operates in Biotechnology and Health Care. Its work centres on iPS cells, ES cells, fertility technology and oocyte creation. Its customers include individuals facing infertility, couples desiring children and healthcare providers.
Dioseve has a B2B, B2C and B2D business model. Its revenue comes from Service Fee, Licensing and Performance Based.
Dioseve has approximately 5 employees.
Dioseve has completed 2 funding rounds, raising a total of $407.00M.
Dioseve offers: developing solutions for infertility using stem cell technology, inducing egg and sperm cells from iPS cells, innovative reproductive health solutions.
Top alternatives and competitors to Dioseve include Pinnacle Washington, Ivy Natal, IRMS Institute for Reproductive Medicine, VitaVitro Biotech, Proov. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dioseve and Pinnacle Washington are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dioseve, https://bouncewatch.com/company/dioseve, updated 24 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes